-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The interleukin-17 family contains 6 subtypes, of which.
Recently, researchers investigated the efficacy, safety and tolerability of solozumab in patients with plaque psoriasis.
The research group was carried out in 41 medical institutions in Bulgaria, Canada, the Czech Republic, Germany, Hungary, Poland and the United States.
313 patients participated in the study, including 52 people in the placebo group, 52 people in the solomizumab 30 mg group, 52 people in the solovizumab 60 mg group, 53 people in the solovizumab 120 mg normal load group, and solo There were 51 people in the Cizumab 120 mg enhanced load group and 53 people in the secukinumab 300 mg group.
0 people (0%) in the placebo group, 25 people (48.
Studies believe that the 30-120mg doses of solozumab all show good therapeutic effects for moderate to severe plaque psoriasis, which has the characteristics of rapid onset, long-lasting improvement, and better safety .
Solocizumab 30-120mg doses all show good therapeutic effects for moderate to severe plaque psoriasis.
Original source:
Kim A Papp et al.
IL17A/F nanobody sonelokimab in patients with plaque psoriasis: a multicentre, randomised, placebo-controlled, phase 2b study.
Leave a message here